ATE199398T1 - Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein - Google Patents

Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein

Info

Publication number
ATE199398T1
ATE199398T1 AT98112614T AT98112614T ATE199398T1 AT E199398 T1 ATE199398 T1 AT E199398T1 AT 98112614 T AT98112614 T AT 98112614T AT 98112614 T AT98112614 T AT 98112614T AT E199398 T1 ATE199398 T1 AT E199398T1
Authority
AT
Austria
Prior art keywords
signal peptide
human protein
secretion
gamma interferon
interferon signal
Prior art date
Application number
AT98112614T
Other languages
English (en)
Inventor
Michael Kriegler
Carl F Perez
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE199398T1 publication Critical patent/ATE199398T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98112614T 1989-10-24 1990-10-23 Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein ATE199398T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42698689A 1989-10-14 1989-10-14
US47416990A 1990-02-02 1990-02-02
US48870690A 1990-03-02 1990-03-02

Publications (1)

Publication Number Publication Date
ATE199398T1 true ATE199398T1 (de) 2001-03-15

Family

ID=27411529

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98112614T ATE199398T1 (de) 1989-10-24 1990-10-23 Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
AT91901031T ATE212672T1 (de) 1989-10-24 1990-10-23 System zur freisetzung von infektiösen proteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT91901031T ATE212672T1 (de) 1989-10-24 1990-10-23 System zur freisetzung von infektiösen proteinen

Country Status (8)

Country Link
US (6) US5324655A (de)
EP (2) EP0497922B1 (de)
JP (2) JP3203599B2 (de)
AT (2) ATE199398T1 (de)
AU (2) AU661652B2 (de)
CA (1) CA2067821A1 (de)
DE (2) DE69033710T2 (de)
WO (1) WO1991006658A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
ATE199398T1 (de) * 1989-10-24 2001-03-15 Chiron Corp Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
CA2104396C (en) * 1991-02-19 2000-10-10 Jiing-Kuan Yee Viral particles having altered host range
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
CA2158936C (en) 1993-11-18 2012-02-21 Jack R. Barber Compositions and methods for utilizing conditionally lethal genes
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
WO2000066608A1 (en) * 1999-04-30 2000-11-09 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US20020111325A1 (en) * 1997-11-03 2002-08-15 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ATE510908T1 (de) * 2000-09-28 2011-06-15 Bioriginal Food & Science Corp Fad5-2, mitglied der desaturase-familie und verwendungen davon
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
EP1556072B1 (de) 2002-09-17 2010-05-19 Antigen Express, Inc. Ii-key/antigene epitop-hybrid-peptid-vakzine
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
DE10362104B4 (de) * 2003-08-29 2008-02-14 Kist-Europe Forschungsgesellschaft Mbh Zellprozessor zur Krankheitsbehandlung
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
AU2005294265A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
EP1856526A4 (de) 2005-01-20 2008-11-12 Univ Rochester Mit thioredoxin interagierendes protein (txnip) als regulator der gefässfunktion
CN112480257A (zh) 2005-03-23 2021-03-12 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
WO2009067216A1 (en) * 2007-11-20 2009-05-28 Beth Israel Deaconess Medical Center Transfection reagent
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
US8772238B2 (en) 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
EP4218794A3 (de) 2009-06-10 2023-09-13 New York University Immunologisches targeting pathologischer tau-proteine
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
EP3970736A1 (de) 2009-11-02 2022-03-23 Emory University Wirkstoffresistente immuntherapie zur krebsbehandlung
EP2658567A4 (de) 2010-12-28 2014-09-24 Univ Rochester Verfahren zur modifikation einer insulinsignalübertragung mittels biliverdinreduktase (bvr) und bvr-abgeleiteten peptiden
DK2753346T3 (da) 2011-09-07 2020-05-25 Sinai School Medicine Ceramidase og celledifferentiering
US9694050B2 (en) 2012-10-21 2017-07-04 University Of Rochester THY1 (CD90) as a novel therapy to control adipose tissue accumulation
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
US12005078B2 (en) 2015-09-03 2024-06-11 The Uab Research Foundation Genetically engineered drug resistant T cells and methods of using the same
EP3371211A4 (de) 2015-11-04 2019-08-21 Icahn School of Medicine at Mount Sinai Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GR78180B (de) * 1982-04-15 1984-09-26 Genentech Inc
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4663281A (en) * 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
WO1985005629A1 (en) * 1984-05-25 1985-12-19 Dana-Farber Cancer Institute Ltr vectors, methods of preparation and use
WO1985005618A1 (en) * 1984-06-06 1985-12-19 Takeda Chemical Industries, Ltd. Process for preparing interferon derivative
WO1986000930A1 (en) * 1984-07-20 1986-02-13 Worcester Foundation For Experimental Biology Retroviral vaccines and vectors and methods for their construction
EP0192658A4 (de) * 1984-07-30 1987-07-13 Salk Inst For Biological Studi Retrovirale gentransfervektoren.
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
DE3581730D1 (de) * 1984-10-15 1991-03-14 Cetus Corp Menschlicher tumornekrosisfaktor.
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
DE3585690D1 (de) * 1984-12-21 1992-04-23 Biogen Inc Reinigung, herstellung und verwendung von tumor-nekrosisfaktoren.
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
EP0196864A3 (de) * 1985-03-25 1988-03-23 Cetus Corporation Behandlung und Sekretion von rekombinanten Proteinen mittels alkalischer Phosphatase, dazu verwendbare DNA-Sequenzen und mittels dieser Sequenzen transformierte Zellen
JP2703893B2 (ja) * 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ 外来遺伝子物質を発現する上皮細胞
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
EP0247906B1 (de) * 1986-02-04 1994-12-28 Mizuno, Den'Ichi Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
AU601956B2 (en) * 1986-03-07 1990-09-27 Cetus Corporation Recombinant ricin toxin
US5206352A (en) * 1986-03-28 1993-04-27 Board Of Trustees Of The University Of Illinois Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
US4752565A (en) * 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
FR2606029B2 (fr) * 1986-04-08 1989-02-03 Transgene Sa Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4868119A (en) * 1986-12-11 1989-09-19 Genetics Institute, Inc. Hematopoietic growth factors
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
JPS6332486A (ja) * 1986-07-25 1988-02-12 Teijin Ltd 新規生理活性ポリペプチド
FR2606030B1 (fr) * 1986-10-31 1989-10-20 Pasteur Institut Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
EP0832981A1 (de) * 1987-02-17 1998-04-01 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
DE3854313D1 (de) * 1987-05-29 1995-09-21 Dana Farber Cancer Inst Inc Cis-Wirkung-Repressionen-Sequenzen, Cis-Wirkung-Antirepressionen-Sequenzen, Vektoren, Verfahren zur Vorbereitung und Anwendung.
EP0317649A4 (en) * 1987-06-17 1990-11-28 Teijin Limited Novel plasmid, microbial cells, process for preparing polypeptide with oncostatic activity, and secreted polypeptide with oncostatic activity
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3876327D1 (de) * 1987-07-21 1993-01-14 Du Pont Merck Pharma Verfahren fuer die herstellung von in tierischen zellen stabilen und lebensfaehigen rekombinanten viralen vektoren.
US5306631A (en) * 1987-08-21 1994-04-26 University Of Colorado Foundation, Inc. Compositions and method for inhibition of HIV production
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US5246924A (en) * 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
EP0378576B1 (de) * 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduktionsveränderte fibroblasten und ihre anwendung
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
JP2914692B2 (ja) * 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
AU3069189A (en) * 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
CN1038306A (zh) * 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
JPH0797997B2 (ja) * 1988-04-28 1995-10-25 帝人株式会社 新規生理活性ポリペプチド
EP0437610B1 (de) * 1988-09-22 1996-06-12 Teijin Limited Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
DE3841762A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5032519A (en) * 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
ATE199398T1 (de) * 1989-10-24 2001-03-15 Chiron Corp Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
US5281475A (en) * 1991-10-17 1994-01-25 W. L. Gore & Associates, Inc. Continuous polytetrafluoroethylene fibers
GB2268853A (en) * 1992-07-09 1994-01-19 Secr Defence Colour television display projection device

Also Published As

Publication number Publication date
EP0897987A3 (de) 1999-03-03
EP0897987A2 (de) 1999-02-24
WO1991006658A2 (en) 1991-05-16
JP2000270883A (ja) 2000-10-03
DE69033911D1 (de) 2002-03-14
EP0897987B1 (de) 2001-02-28
US5874077A (en) 1999-02-23
JP3203599B2 (ja) 2001-08-27
JPH05504681A (ja) 1993-07-22
US6071512A (en) 2000-06-06
EP0497922B1 (de) 2002-01-30
AU661652B2 (en) 1995-08-03
AU6956691A (en) 1991-05-31
US5863797A (en) 1999-01-26
AU3664695A (en) 1996-03-21
DE69033710D1 (de) 2001-04-12
CA2067821A1 (en) 1991-04-25
ATE212672T1 (de) 2002-02-15
WO1991006658A3 (en) 1991-10-17
US5889156A (en) 1999-03-30
US5324655A (en) 1994-06-28
EP0497922A1 (de) 1992-08-12
DE69033710T2 (de) 2001-06-13
US5849586A (en) 1998-12-15

Similar Documents

Publication Publication Date Title
ATE199398T1 (de) Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
ATE122397T1 (de) Fusionsproteine aus interleukin-2 und hirudin.
ES2080098T3 (es) Expresion de la proteina de union i al factor de necrosis tumoral tbp-i recombinante.
DE3881776D1 (de) Dns-konstruktionen, enthaltend eine kluyveromyces-alpha-factor-leadersequenz zur leitung der sekretion von heterologen polypeptiden.
FR2514783B1 (fr) Interferon immunitaire humain
ATA257190A (de) Virales polypeptid
DK134790D0 (da) Dna, der koder ige receptor alfa-subenhed eller fragment heraf
SE9101433D0 (sv) Recombinant dna sequence and its use
ATE84798T1 (de) Transformierender wachstumsfaktor-beta.
DE3786649D1 (de) Pferde-gamma-interferon.
IL87391A0 (en) Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
NO873216D0 (no) Rekombinante htlv-iii-proteiner og anvendelse derav.
AU8755591A (en) Gro genes, proteins, and uses thereof
EP0620860A4 (en) Preparation of recombinant borrelia proteins.
IL90134A (en) Recombinant dna molecule encoding for plasmodium falciparum surface protein of zygotes and ookinetes and pharmaceutical compositions containing said protein prepared by expressing said dna
DE3881123D1 (de) Klonieren von fuer einen antibakteriellen polypeptidvorlaeufer kodierender dna und expression des vorlaeufers.
ATE254179T1 (de) Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen
FR2481316B1 (fr) Technique a adn de recombinant pour la preparation d'une proteine ressemblant a l'interferon humain
FI895456A0 (fi) Rekombinant interleukin 2-hybridproteiner.
ATE111920T1 (de) Lymphokine, dns-sequenzen, die diese lymphokine kodieren, und sie enthaltende pharmazeutische zusammensetzungen.
ITFI920071A0 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vogeesndk
NO875477D0 (no) Rekombinant alveolaert overflateaktivt protein.
DK527287D0 (da) Polypeptid med interleukin-2-aktiviteter
ZA928032B (en) Preparation of recombinant borrelia proteins.